17 results on '"Jodeleit H"'
Search Results
2. OP12 Targeting inflammation in ulcerative colitis by inhibiting glucose uptake
- Author
-
Gropp, R, primary, Jodeleit, H, additional, Caesar, J, additional, Villarroel Aguilera, C, additional, Beigel, F, additional, Breiteneicher, S, additional, Stallhofer, J, additional, and Siebeck, M, additional
- Published
- 2019
- Full Text
- View/download PDF
3. CD1a expressing monocytes as potential therapeutic targets in ulcerative colitis
- Author
-
Al-amodi, O, additional, Jodeleit, H, additional, Beigel, F, additional, Wolf, E, additional, Gropp, R, additional, and Siebeck, M, additional
- Published
- 2018
- Full Text
- View/download PDF
4. Targeting inflammation in ulcerative colitis by inhibition of glucose uptake
- Author
-
Jodeleit, H, additional, Al-amodi, O, additional, Caesar, J, additional, Villarroel Aguilera, C, additional, Holdt, L, additional, Gropp, R, additional, Beigel, F, additional, and Siebeck, M, additional
- Published
- 2018
- Full Text
- View/download PDF
5. Targeting Ulcerative Colitis with Ritonavir
- Author
-
Jodeleit, H, additional, Al-amodi, O, additional, Caesar, J, additional, Schütze, G, additional, Holdt, L, additional, Siebeck, M, additional, Gropp, R, additional, and Beigel, F, additional
- Published
- 2018
- Full Text
- View/download PDF
6. CD1a expressing monocytes as sensors and mediators of inflammation in ulcerative colitis
- Author
-
Al-amodi, O, additional, Jodeleit, H, additional, Beigel, F, additional, Wolf, E, additional, Siebeck, M, additional, and Gropp, R, additional
- Published
- 2018
- Full Text
- View/download PDF
7. Failure to control inflammation as a driving force of symptoms and phenotype in the NSG mouse model of ulcerative colitis
- Author
-
Jodeleit, H, additional, Palamides, P, additional, Al-amodi, O, additional, Beikircher, G, additional, Schönthaler, S, additional, Wolf, E, additional, Weinhäusel, A, additional, Beigel, F, additional, Siebeck, M, additional, and Gropp, R, additional
- Published
- 2018
- Full Text
- View/download PDF
8. P096 Failure to control inflammation as a driving force of symptoms and phenotype in the NSG mouse model of ulcerative colitis
- Author
-
Jodeleit, H, primary, Palamides, P, additional, Al-amodi, O, additional, Beikircher, G, additional, Schönthaler, S, additional, Beigel, F, additional, Wolf, E, additional, Weinhäusel, A, additional, Siebeck, M, additional, and Gropp, R, additional
- Published
- 2018
- Full Text
- View/download PDF
9. P083 CD1a expressing monocytes as sensors and mediators of inflammation in ulcerative colitis
- Author
-
Al-amodi, O, primary, Jodeleit, H, additional, Beigel, F, additional, Wolf, E, additional, Siebeck, M, additional, and Gropp, R, additional
- Published
- 2018
- Full Text
- View/download PDF
10. Adipocyte function and the development of cardiometabolic disease.
- Author
-
Giroud M, Jodeleit H, Prentice KJ, and Bartelt A
- Subjects
- Adipocytes, Brown metabolism, Adipose Tissue, Brown physiology, Adipose Tissue, White metabolism, Animals, Diet, High-Fat adverse effects, Energy Metabolism, Mice, Obesity metabolism, Thermogenesis physiology, Cardiovascular Diseases etiology, Cardiovascular Diseases metabolism
- Abstract
Obesity is a medical disorder caused by multiple mechanisms of dysregulated energy balance. A major consequence of obesity is an increased risk to develop diabetes, diabetic complications and cardiovascular disease. While a better understanding of the molecular mechanisms linking obesity, insulin resistance and cardiovascular disease is needed, translational research of the human pathology is hampered by the available cellular and rodent model systems. Major barriers are the species-specific differences in energy balance, vascular biology and adipose tissue physiology, especially related to white and brown adipocytes, and adipose tissue browning. In rodents, non-shivering thermogenesis is responsible for a large part of energy expenditure, but humans possess much less thermogenic fat, which means temperature is an important variable in translational research. Mouse models with predisposition to dyslipidaemia housed at thermoneutrality and fed a high-fat diet more closely reflect human physiology. Also, adipocytes play a key role in the endocrine regulation of cardiovascular function. Adipocytes secrete a variety of hormones, lipid mediators and other metabolites that directly influence the local microenvironment as well as distant tissues. This is specifically apparent in perivascular depots, where adipocytes modulate vascular function and inflammation. Altogether, these mechanisms highlight the critical role of adipocytes in the development of cardiometabolic disease., (© 2021 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society.)
- Published
- 2022
- Full Text
- View/download PDF
11. Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγnull mice reconstituted with human peripheral blood mononuclear cells.
- Author
-
Jodeleit H, Winkelmann P, Caesar J, Sterz S, Holdt LM, Beigel F, Stallhofer J, Breiteneicher S, Bartnik E, Leeuw T, Siebeck M, and Gropp R
- Subjects
- Adult, Aged, Aged, 80 and over, Animals, Antigens, CD metabolism, Antigens, Differentiation, T-Lymphocyte metabolism, CD4-Positive T-Lymphocytes cytology, Colitis, Ulcerative physiopathology, Disease Models, Animal, Female, Humans, Interleukin Receptor Common gamma Subunit metabolism, Lectins, C-Type metabolism, Male, Mice, Mice, Inbred NOD, Mice, SCID, Middle Aged, OX40 Ligand metabolism, Principal Component Analysis, Receptors, OX40 metabolism, Treatment Outcome, Young Adult, Adalimumab pharmacology, Antibodies, Monoclonal chemistry, Colitis, Ulcerative genetics, Colitis, Ulcerative metabolism, Leukocytes, Mononuclear cytology, OX40 Ligand chemistry, Receptors, OX40 genetics
- Abstract
This study's aim was to demonstrate that the combination of patient immune profiling and testing in a humanized mouse model of ulcerative colitis (UC) might lead to patient stratification for treatment with oxelumab. First, immunological profiles of UC patients and non-UC donors were analyzed for CD4+ T cells expressing OX40 (CD134; also known as TNFRSF4) and CD14+ monocytes expressing OX40L (CD252; also known as TNFSF4) by flow cytometric analysis. A significant difference was observed between the groups for CD14+ OX40L+ (UC: n=11, 85.44±21.17, mean±s.d.; non-UC: n=5, 30.7±34.92; P=0.02), whereas no significant difference was detected for CD4+ OX40+. CD14+ OX40L+ monocytes were correlated significantly with T helper 1 and 2 cells. Second, NOD/Scid IL2Rγ null mice were reconstituted with peripheral blood mononuclear cells from UC donors exhibiting elevated levels of OX40L, and the efficacy of oxelumab was compared with that of adalimumab. The clinical, colon and histological scores and the serum concentrations of IL-6, IL-1β and glutamic acid were assessed. Treatment with oxelumab or adalimumab resulted in significantly reduced clinical, colon and histological scores, reduced serum concentrations of IL-6 and reduced frequencies of splenic human effector memory T cells and switched B cells. Comparison of the efficacy of adalimumab and oxelumab by orthogonal partial least squares discrimination analysis revealed that oxelumab was slightly superior to adalimumab; however, elevated serum concentrations of glutamic acid suggested ongoing inflammation. These results suggest that oxelumab addresses the pro-inflammatory arm of inflammation while promoting the remodeling arm and that patients exhibiting elevated levels of OX40L might benefit from treatment with oxelumab., Competing Interests: Competing interests The authors declare no competing or financial interests., (© 2021. Published by The Company of Biologists Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
12. The Combination of Patient Profiling and Preclinical Studies in a Mouse Model Based on NOD/Scid IL2Rγ null Mice Reconstituted With Peripheral Blood Mononuclear Cells From Patients With Ulcerative Colitis May Lead to Stratification of Patients for Treatment With Adalimumab.
- Author
-
Jodeleit H, Caesar J, Villarroel Aguilera C, Sterz S, Holdt L, Beigel F, Stallhofer J, Breiteneicher S, Bartnik E, Siebeck M, and Gropp R
- Subjects
- Adalimumab therapeutic use, Adult, Aged, Animals, Colitis, Ulcerative drug therapy, Colitis, Ulcerative metabolism, Colon pathology, Disease Models, Animal, Female, Humans, Inflammation pathology, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear immunology, Longitudinal Studies, Male, Mice, Mice, Inbred NOD, Mice, SCID, Middle Aged, Monocytes drug effects, Monocytes metabolism, Spleen pathology, T-Lymphocytes, Helper-Inducer drug effects, T-Lymphocytes, Helper-Inducer immunology, T-Lymphocytes, Helper-Inducer metabolism, Young Adult, Adalimumab pharmacology, Colitis, Ulcerative blood, Colitis, Ulcerative pathology, Leukocytes, Mononuclear metabolism
- Abstract
Background: To date, responsiveness to tumor necrosis factor alpha inhibitors in ulcerative colitis (UC) patients is not predictable. This is partially due to a lack of understanding of the underlying inflammatory processes. The aim of this study was to identify immunological subgroups of patients with UC and to test responsiveness to adalimumab in these subgroups in the mouse model of ulcerative colitis (UC), which is based on NOD/scid IL-2Rγ null (NSG) mice reconstituted with peripheral blood mononuclear cells (PBMCs; NSG-UC)., Methods: The immunological profiles of 40 UC patients and 16 non-UC donors were determined by flow cytometric analysis of PBMCs in a snapshot and longitudinal study and analyzed by principal component, orthogonal partial least square discrimination (oPLS-DA), and hierarchical clustering analysis. NSG mice were reconstituted 5 times at consecutive time points with PBMCs from a single donor and were analyzed for frequencies of human leukocytes and histological phenotype. The response to adalimumab of 2 identified subgroups was tested in the NSG-UC model. We used the clinical, colon, and histological score, serum levels of glutamic and aspartic acid, and IL-6 and IL-1ß. Response was analyzed by oPLS-DA., Results: Analysis revealed a distinction between UC and non-UC donors. Hierarchical clustering identified 2 major subgroups in UC patients. Group I was characterized by TH17 and M1 monocytes, group II by TH2/TH1, and switched B cells. These subgroups reflect the dynamics of inflammation as patients. NSG-UC mice achieved an immunological phenotype reflecting the patient's immunological phenotype. oPLS-DA revealed that NSG-UC mice reconstituted with PBMCs from group II responded better to adalimumab., Conclusions: The combination of profiling and testing of therapeutics in the NSG-UC model may lead to individualized and phase-dependent therapies., (© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.)
- Published
- 2020
- Full Text
- View/download PDF
13. Autoantibodies as diagnostic markers and potential drivers of inflammation in ulcerative colitis.
- Author
-
Jodeleit H, Milchram L, Soldo R, Beikircher G, Schönthaler S, Al-Amodi O, Wolf E, Beigel F, Weinhäusel A, Siebeck M, and Gropp R
- Subjects
- Adult, Aged, Animals, Autoantibodies immunology, Biomarkers blood, Cells, Cultured, Colitis, Ulcerative blood, Colitis, Ulcerative immunology, Cytokines blood, Female, Humans, Male, Mice, Mice, Inbred NOD, Mice, SCID, Middle Aged, Autoantibodies blood, Colitis, Ulcerative diagnosis
- Abstract
To date, no comprehensive analysis of autoantibodies in sera of patients with ulcerative colitis has been conducted. To analyze the spectrum of autoantibodies and to elucidate their role serum-IgG from UC patients (n = 49) and non-UC donors (n = 23) were screened by using a human protein microarray. Screening yielded a remarkable number of 697 differentially-reactive at the nominal 0·01 significance level (FDR<0·1) of the univariate test between the UC and the non-UC group. CD99 emerged as a biomarker to discriminate between both groups (p = 1e-04, AUC = 0·8). In addition, cytokines, chemokines and growth factors were analyzed by Olink's Proseek® Multiplex Inflammation-I 96×96 immuno-qPCR assay and 31 genes were significant at the nominal 0.05 level of the univariate test to discriminate between UC and non-UC donors. MCP-3, HGF and CXCL-9 were identified as the most significant markers to discriminate between UC patients with clinically active and inactive disease. Levels of CXCL10 (cor = 0.3; p = 0.02), CCL25 (cor = 0.25; p = 0.04) and CCL28 (cor = 0.3; p = 0.02) correlated positively with levels of anti CD99. To assess whether autoantibodies are detectable prior to diagnosis with UC, sera from nine donors at two different time points (T-early, median 21 months and T-late, median 6 months) were analyzed. 1201 features were identified with higher reactivity in samples at time points closer to clinical UC presentation. In vitro, additional challenge of peripheral mononuclear cells with CD99 did not activate CD4+ T cells but induced the secretion of IL-10 (-CD99: 20.21±20.25; +CD99: 130.20±89.55; mean ±sd; p = 0.015). To examine the effect of CD99 in vivo, inflammation and autoantibody levels were examined in NOD/ScidIL2Rγnull mice reconstituted with PBMC from UC donors (NSG-UC). Additional challenge with CD99 aggravated disease symptoms and pathological phenotype as indicated by the elevated clinical score (-CD99: 1·85 ± 1·94; +CD99: 4·25 ± 1·48) and histological score (-CD99: 2·16 ± 0·83; +CD99: 3·15 ± 1·16, p = 0·01). Furthermore, levels of anti-CD99 antibodies increased (Control: 398 ± 323; mean MFI ± sd; Ethanol + PBS: 358 ±316; Ethanol + CD99: 1363 ± 1336; Control versus Ethanol + CD99: p = 0.03). In a highly inflammatory environment, frequencies of pro-inflammatory M1 monocytes (CD14+ CD64+: unchallenged 8.09±4.72; challenged 14.2±8.62; p = 0.07; CD14+ CD1a+: unchallenged 16.29 ±6.97; challenged 43.81±14.4, p = 0.0003) increased and levels of autoantibodies in serum decreased in the NSG-UC mouse model. These results suggest that autoantibodies are potent biomarkers to discriminate between UC and non-UC and indicate risk to develop UC. In an inflammatory environment, auto-antibodies may promote the pathological phenotype by activating M1 monocytes in the NSG-UC animal model and also in patients with UC., Competing Interests: The authors Andreas Weinhäusel, Regina Soldo, Lisa Milchram and Gabriel Beikircher are employees of the Austrian Institute of Technology (AIT). The funder provided support in the form of salaries for authors [L.M., R.S., G.B., A.W.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2020
- Full Text
- View/download PDF
14. Targeting ulcerative colitis by suppressing glucose uptake with ritonavir.
- Author
-
Jodeleit H, Al-Amodi O, Caesar J, Villarroel Aguilera C, Holdt L, Gropp R, Beigel F, and Siebeck M
- Subjects
- Adult, Aged, 80 and over, Animals, Aspartic Acid blood, Biomarkers metabolism, CD4-Positive T-Lymphocytes immunology, Colitis, Ulcerative blood, Colitis, Ulcerative immunology, Disease Models, Animal, Female, Glutamic Acid blood, Humans, Inflammation pathology, Leukocytes metabolism, Male, Middle Aged, Phenotype, Principal Component Analysis, Colitis, Ulcerative drug therapy, Glucose metabolism, Ritonavir therapeutic use
- Abstract
Glucose is the preferred source of energy in activated inflammatory cells. Glucose uptake into the cell is ensured by a family of glucose uptake transporters (GLUTs), which have been identified as off-target molecules of the HIV protease inhibitor ritonavir. In this study, we examined the effect of ritonavir on inflammation in vitro and in vivo Peripheral blood mononuclear cells (PBMCs) were activated with anti-CD3 in the presence or absence of ritonavir and analyzed by flow cytometric analysis. Frequencies of CD4+ cells were significantly affected by ritonavir (CD69+ P =3E-05; CD134 P =4E-06; CD25+ P =E-07; central memory P =0.02; effector P =6E-03; effector memory P =6E-05). To corroborate that inflammation has a metabolic effect in vivo , a mouse model was used that is based on immunocompromised NOD-scid IL-2Rγ
null mice reconstituted with PBMCs from patients with ulcerative colitis (UC). Inflammation had a significant effect on amino acid (AA) levels (Glu P =1E-07, Asp P =1E-04). Principal component analysis (PCA) discriminated between unchallenged and challenged groups. Finally, the efficacy of ritonavir was tested in the same mouse model. Dependent variables were clinical and histological scores, frequencies of human leukocytes isolated from spleen and colon, and levels of AA in sera of mice. Mice benefited from treatment with ritonavir as indicated by significantly decreased colon ( P =7E-04) and histological ( P =1E-04) scores, frequencies of M2 monocytes (CD14+ CD163; P =0.02), and Glu levels ( P =2E-05). PCA discriminated between control and challenged groups ( P =0.026). Thus, inhibition of glucose uptake might be a promising therapeutic intervention point for active UC., Competing Interests: Competing interestsThe authors declare no competing or financial interests., (© 2018. Published by The Company of Biologists Ltd.)- Published
- 2018
- Full Text
- View/download PDF
15. CD1a-Expressing Monocytes as Mediators of Inflammation in Ulcerative Colitis.
- Author
-
Al-Amodi O, Jodeleit H, Beigel F, Wolf E, Siebeck M, and Gropp R
- Abstract
Background: CD1a-expressing CD14+ monocytes have been identified as inducers of autoreactive T cells. In this study, the link between inflammatory and metabolic signals and CD1a-expressing monocytes in vitro and in vivo was examined, and CD1a was evaluated as a potential therapeutic target for treatment of ulcerative colitis (UC)., Methods: Peripheral blood mononuclear cells (PBMCs) from UC patients and non-UC donors were incubated with phosphatidylcholine (PC) for 2 and 7 days and subjected to flow cytometric analysis. Triacylglycerol (TAG) and cholesterol levels and frequencies of CD14+ CD1a+ monocytes were determined in a mouse model of UC that is based on NOD/scid IL2Rγnull mice reconstituted with PBMCs from UC patients (NSG-UC). NSG-UC mice were treated with anti-CD1a antibodies. Response to treatment was determined by clinical and histological scores, flow cytometric analysis of human leucocytes from the spleen and colon, and expression levels of TGFß1, HGF, IFNγ, and TARC., Results: Incubation of PBMCs with PC resulted in an increase of the frequency of CD1a+ CD14+ monocytes at the expense of CCR2-, CD86-, and TSLPR-expressing CD14+ monocytes. CD1a+ CD14+ monocytes induced the activation of CD4+ T cells and differentiation of Th cells. In vivo, TAG and cholesterol levels increased upon inflammation and correlated positively with CD14+ CD1a+ monocytes. NSG-UC mice benefitted from treatment with anti-CD1a antibodies, as indicated by a reduced histological score and reduced frequencies of CD1a+ CD14+ monocytes in the colon and spleen of mice., Conclusion: CD1a-expressing monocytes might act as sensors and mediators of inflammation in UC. Mice benefitted from treatment with anti-CD1a antibodies., (© 2018 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.)
- Published
- 2018
- Full Text
- View/download PDF
16. Design and validation of a disease network of inflammatory processes in the NSG-UC mouse model.
- Author
-
Jodeleit H, Palamides P, Beigel F, Mueller T, Wolf E, Siebeck M, and Gropp R
- Subjects
- Adult, Aged, Animals, Colitis, Ulcerative drug therapy, Colitis, Ulcerative genetics, Ethanol, Female, Gene Expression Regulation drug effects, Humans, Inflammation drug therapy, Inflammation genetics, Infliximab pharmacology, Infliximab therapeutic use, Interleukin-4 pharmacology, Interleukin-4 therapeutic use, Macrophages metabolism, Male, Mice, Inbred NOD, Mice, SCID, Middle Aged, Monocytes metabolism, RNA, Messenger genetics, RNA, Messenger metabolism, Reproducibility of Results, Colitis, Ulcerative pathology, Inflammation pathology
- Abstract
Background: Ulcerative colitis (UC) is a highly progressive inflammatory disease that requires the interaction of epithelial, immune, endothelial and muscle cells and fibroblasts. Previous studies suggested two inflammatory conditions in UC-patients: 'acute' and 'remodeling' and that the design of a disease network might improve the understanding of the inflammatory processes. The objective of the study was to design and validate a disease network in the NOD-SCID IL2rγ
null (NSG)-UC mouse model to get a better understanding of the inflammatory processes., Methods: Leukocytes were isolated from the spleen of NSG-UC mice and subjected to flow cytometric analysis. RT-PCR and RNAseq analysis were performed from distal parts of the colon. Based on these analyses and the effects of interleukins, chemokines and growth factors described in the literature, a disease network was designed. To validate the disease network the effect of infliximab and pitrakinra was tested in the NSG-UC model. A clinical- and histological score, frequencies of human leukocytes isolated from spleen and mRNA expression levels from distal parts of the colon were determined., Results: Analysis of leukocytes isolated from the spleen of challenged NSG-UC mice corroborated CD64, CD163 and CD1a expressing CD14+ monocytes, CD1a expressing CD11b+ macrophages and HGF, TARC, IFNγ and TGFß1 mRNA as inflammatory markers. The disease network suggested that a proinflammatory condition elicited by IL-17c and lipids and relayed by cytotoxic T-cells, Th17 cells and CD1a expressing macrophages and monocytes. Conversely, the remodeling condition was evoked by IL-34 and TARC and promoted by Th2 cells and M2 monocytes. Mice benefitted from treatment with infliximab as indicated by the histological- and clinical score. As predicted by the disease network infliximab reduced the proinflammatory response by suppressing M1 monocytes and CD1a expressing monocytes and macrophages and decreased levels of IFNγ, TARC and HGF mRNA. As predicted by the disease network inflammation aggravated in the presence of pitrakinra as indicated by the clinical and histological score, elevated frequencies of CD1a expressing macrophages and TNFα and IFNγ mRNA levels., Conclusions: The combination of the disease network and the NSG-UC animal model might be developed into a powerful tool to predict efficacy or in-efficacy and potential mechanistic side effects.- Published
- 2017
- Full Text
- View/download PDF
17. A mouse model for ulcerative colitis based on NOD-scid IL2R γnull mice reconstituted with peripheral blood mononuclear cells from affected individuals.
- Author
-
Palamides P, Jodeleit H, Föhlinger M, Beigel F, Herbach N, Mueller T, Wolf E, Siebeck M, and Gropp R
- Subjects
- Animals, Cell Shape drug effects, Colitis, Ulcerative drug therapy, Colitis, Ulcerative metabolism, Colon pathology, Disease Models, Animal, Ethanol, Hepatocyte Growth Factor metabolism, Humans, Inflammation pathology, Infliximab pharmacology, Infliximab therapeutic use, Interleukin Receptor Common gamma Subunit metabolism, Interleukin-4 pharmacology, Interleukin-4 therapeutic use, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear immunology, Lipopolysaccharide Receptors metabolism, Mice, Inbred NOD, Mice, SCID, Monocytes drug effects, Monocytes metabolism, Spleen pathology, T-Lymphocytes drug effects, T-Lymphocytes metabolism, Transforming Growth Factor beta1 metabolism, Colitis, Ulcerative blood, Colitis, Ulcerative pathology, Interleukin Receptor Common gamma Subunit deficiency, Leukocytes, Mononuclear metabolism
- Abstract
Animal models reflective of ulcerative colitis (UC) remain a major challenge, and yet are crucial to understand mechanisms underlying the onset of disease and inflammatory characteristics of relapses and remission. Mouse models in which colitis-like symptoms are induced through challenge with toxins such as oxazolone, dextran sodium sulfate (DSS) or 2,4,6-trinitrobenzenesulfonic acid (TNBS) have been instrumental in understanding the inflammatory processes of UC. However, these neither reflect the heterogeneous symptoms observed in the UC-affected population nor can they be used to test the efficacy of inhibitors developed against human targets where high sequence and structural similarity of the respective ligands is lacking. In an attempt to overcome these problems, we have developed a mouse model that relies on NOD-scid IL2R γ(null) mice reconstituted with peripheral blood mononuclear cells derived from UC-affected individuals. Upon challenge with ethanol, mice developed colitis-like symptoms and changes in the colon architecture, characterized by influx of inflammatory cells, edema, crypt loss, crypt abscesses and epithelial hyperplasia, as previously observed in immune-competent mice. TARC, TGFβ1 and HGF expression increased in distal parts of the colon. Analysis of human leucocytes isolated from mouse spleen revealed an increase in frequencies of CD1a+, CD64+, CD163+ and TSLPR+ CD14+ monocytes, and antigen-experienced CD44+ CD4+ and CD8+ T-cells in response to ethanol. Analysis of human leucocytes from the colon of challenged mice identified CD14+ monocytes and CD11b+ monocytes as the predominant populations. Quantitative real-time PCR (RT-PCR) analysis from distal parts of the colon indicated that IFNγ might be one of the cytokines driving inflammation. Treatment with infliximab ameliorated symptoms and pathological manifestations, whereas pitrakinra had no therapeutic benefit. Thus, this model is partially reflective of the human disease and might help to increase the translation of animal and clinical studies., Competing Interests: The authors declare no competing or financial interests., (© 2016. Published by The Company of Biologists Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.